95301-49-8

Upstream product

• 3344-70-5 1,12-dibromododecane 
• 100-51-6 benzyl alcohol 
• 3344-77-2 12-bromododecanol 
• 100-39-0 benzyl bromide 
• 134834-32-5 12-(benzyloxy)dodecan-1-ol 
• 5675-51-4 1,12-dodecandiol 

Downstream Products

• 147918-42-1 13-(Benzyloxy)-1-(3-pyridyl)-1-tridecanol 
• 39695-18-6 ((dodecyloxy)methyl)benzene 
• 1194767-76-4 methyl (Z)-18-benzyloxy-6-octadecenoate 
• 173288-95-4 12-(benzyloxy)dodecanoic acid 
• 147918-41-0 <13-(3-Pyridyl)tridecyl>-p-toluolsulfonat 
• 147918-43-2 13-(Benzyloxy)-1-(3-pyridyl)-1-tridecanon 
• 147918-40-9 3-<13-(Benzyloxy)tridecyl>pyridin 
• 757971-81-6 {(S)-13-Benzyloxy-1-[(R)-1-((1R,2R)-2-benzyloxy-1-vinyl-tetradecyloxy)-allyl]-tridecyloxy}-tert-butyl-dimethyl-silane 
• 757971-73-6 16-benzyloxy-3-(2-benzyloxy-1-vinyl-tetradecyloxy)-hexadec-1-en-4-ol 
• 757971-74-7 (3S,4R)-16-benzyloxy-3,4-epoxy-hexadec-1-ene 

Relevant academic research and scientific papers

Total Synthesis and Biological Evaluation of Siladenoserinol A and its Analogues

The total synthesis of siladenoserinol A, an inhibitor of the p53–Hdm2 interaction, has been achieved. AuCl3-catalyzed hydroalkoxylation of an alkynoate derivative smoothly and regioselectively proceeded to afford a bicycloketal in excellent yield. A glycerophosphocholine moiety was successfully introduced through the Horner–Wadsworth–Emmons reaction using an originally developed phosphonoacetate derivative. Finally, removal of the acid-labile protecting groups, followed by regioselective sulfamate formation of the serinol moiety afforded the desired siladenoserinol A, and benzoyl and desulfamated analogues were also successfully synthesized. Biological evaluation showed that the sulfamate is essential for biological activity, and modification of the acyl group on the bicycloketal can improve the inhibitory activity against the p53–Hdm2 interaction.

METHOD FOR PREPARING OREGANIC ACID

The present invention is aimed at a process for obtaining oreganic acid and derivatives thereof, to the intermediate compounds of this synthesis and to the use of these compounds in the preparation of oreganic acid and derivatives thereof.

HYDROQUINONE LONG-CHAIN DERIVATIVE AND/OR PHENOXY LONG-CHAIN DERIVATIVE, AND PHARMACEUTICAL PREPARATION COMPRISING THE SAME

The present invention provides compounds represented by formula (1) shown below: (wherein R1, R2, R3, R4, and R5 are each individually selected from among a hydrogen atom, methyl group, acetyl group, hydroxyl group, and alkoxy group; and X represents an alkylene group or alkenylene group); and compounds represented by formula (2) shown below: (wherein R6, R7, R8, R9, and R10 are each individually selected from among a hydrogen atom, alkyl group, acetyl group, hydroxyl group, and alkoxy group; A represents an oxygen atom or NH, and m is 0 or 1; and Y represents an alkylene group or alkenylene group, and Z represents a hydrogen atom or hydroxyl group).The compounds of the present invention are useful for preventing or treating brain dysfunctions, motor dysfunctions, or urinary dysfunctions caused by the degeneration and/or loss of the central nervous system or peripheral nervous system cells.The present invention provides compounds represented by formula (1) shown below: (wherein R 1 , R 2 , R 3 , R 4 , and R 5 are each individually selected from among a hydrogen atom, methyl group, acetyl group, hydroxyl group, and alkoxy group; and X represents an alkylene group or alkenylene group); and compounds represented by formula (2) shown below: (wherein R 6 , R 7 , R 8 , R 9 , and R 10 are each individually selected from among a hydrogen atom, alkyl group, acetyl group, hydroxyl group, and alkoxy group; A represents an oxygen atom or NH, and m is 0 or 1; and Y represents an alkylene group or alkenylene group, and Z represents a hydrogen atom or hydroxyl group). The compounds of the present invention are useful for preventing or treating brain dysfunctions, motor dysfunctions, or urinary dysfunctions caused by the degeneration and/or loss of the central nervous system or peripheral nervous system cells.

Quinol fatty alcohols as promoters of axonal growth

The synthesis of three series of quinol fatty alcohols (QFAs) and their biological activities on the promotion of axonal growth are described. Interestingly, the 15-(2,5-dimethoxyphenyl)pentadecan-1-ol, the QFA bearing 15 carbon atoms on the side chain (n = 15), shows the most potent promotion of axonal growth in the presence of both permissive and non-permissive naturally occurring substrates such as Sema3A and myelin proteins.

Functional synthetic molecules and macromolecules for gene delivery

The present invention describes a synthetic non-viral vector composition for gene therapy and the use of such compositions for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention proposes a pharmaceutical composition containing 1) a non-cationic amphiphilic molecule or macromolecule and its use for delivery of nucleic acids or 2) a cationic amphiphilic molecule or macromolecule that transforms from a cationic entity to an anionic, neutral, or zwitterionic entity by a chemical, photochemical, or biological reaction and its use for delivery of nucleic acids. Moreover this invention describes the use of these non-viral vector compositions in conjunction with a surface to mediate the delivery of nucleic acids. An additional embodiment is the formation of a hydrogel with these compositions and the use of this hydrogel for the delivery of genetic material. A further embodiment of this invention is the use of a change in ionic strength for the delivery of genetic material.

Chiral discrimination of branched-chain fatty acids by reversed-phase HPLC after labeling with a chiral fluorescent conversion reagent

Anteiso fatty acids having 16 to 29 carbon atoms were labeled with the chiral fluorescent conversion reagents, (1R,2R)- and (1S,2S)-2-(2,3- anthracenedicarboximido)-cyclohexanol. The diastereomeric esters of anteiso acids having up to 20 carbon atoms were

Determination of the absolute configurations of the anteiso acid moieties of glycoglycerolipid S365A isolated from Corynebacterium aquaticum

The absolute configurations of the two acid moieties, 12- methyltetradecanoate and 14-methylhexadecanoate, of glycoglycerolipid S365A isolated from Corynebacterium aquaticum were determined by an HPLC analysis after their conversion with the chiral fluore

Enantioselective synthesis of (3R,4E)-19-methylicos-4-en-1-yn-3-ol, a bioactive metabolite of the marine sponge Cribrochalina vasculum

The first stereoselective synthesis of (3R,4E)-19-methylicos-4-en-1-yn- 3-ol, an immunosuppressive and antitumoral metabolite isolated from the Caribbean sponge Cribrochalina vasculum, has been achieved and its stereostructure has been confirmed. The key step of the synthesis involves a borane-mediated reduction of the parent (E)- 19-methyl-1-trimethylsilylicos- 4-en-1-yn-3-one in the presence of a chiral oxazaborolidine.

Synthese der Theonelladine A, B, C, D und von Niphatesin A

The pyridine alkaloids theonelladine A-D (1-4) and niphatesine (5) of marine origin have been synthesized starting either from 3-(4,4-dibromo-3-butenyl)pyridine (6) or from 3-pyridinecarbaldehyde.Reaction of 6 with two equivalents of BuLi gave the lithiated derivative of the alkyne 7, which could be alkylated with 1-bromo-10-(tetrahydro-2-pyranyloxy)decane (8) to yield the alkynol 9 after methanolysis.Selective hydrogenation of 9 with Lindlar palladium catalyst gave (Z)-14-(3-pyridyl)-11-tetradecen-1-ol (11). - Addition of the Grignard reagent of 12-(benzyloxy)-1-bromododecane (13) to 3-pyridinecarbaldehyde gave 17, which was first oxidized (Swern) to give 18 and then reduced (Wolff-Kishner) to give 14.Hydrogenolysis of the benzyl ether 14 yielded 15.The alcohol group in 9, 11, and 15 was converted into the tosyloxy group by reaction with tosyl chloride/pyridine.Subsequent reactions of the tosylates 10, 12, and 16 either with an excess of methylamine/ethanol or of ammonia/ethanol gave the pyridine alkaloids 1-5 in high yields as p-toluenesulfonates. Key Words: Pyridines/Alkaloids/Theonelladines A-D/Niphatesine A/4-(3-Pyridyl)-1-butin.

Catechol derivatives and pharmaceutical compositions thereof for inhibiting anaphylaxis (SRS-A)

A catechol derivative represented by the formula STR1 The compounds of this invention are useful for the prophylaxis and treatment for various allergic diseases, ischemic heart diseases and inflammations caused by slow reacting substance of anaphylaxis (SRS-A), since the compounds inhibit very potently the formation and release of SRS-A.